Sibiriline derivatives for use for preventing and/or treating disorders associated with cellular necroptosis

1. A method for inhibiting cellular necroptosis comprising the administration to a patient in need thereof of an effective amount of a compound of the following general formula (I)

or a pharmaceutically acceptable salt and/or solvate thereof,

wherein:

R 1 is H, a (C 1 -C 6 )alkyl or a (C 3 -C 6 )cycloalkyl, or R 1 forms together with R 2 or R 4 a heterocycloalkyl;

R 2 and R 3 are H;

R 4 to R 6 are, independently of one another, H or OR 10 ;

R 10 is H or (C 1 -C 6 )alkyl;

R 7 is H or halo;

R 8 to R 9 are, independently of one another, H; halo; or a group selected from (C 1 -C 6 )alkyl, heterocycle, aryl, heteroaryl, —(C 1 -C 6 )alkyl-aryl, and —(C 1 -C 6 )alkyl-heterocycle, said group being optionally substituted with one or more groups selected from halo, —OR 36 , —NR 37 R 38 , —SR 39 , —S(O)R 40 , —SO 2 R 41 , —SO 2 NR 42 R 43 , —OCOR 44 , —NR 45 COR 46 , —NR 47 C(O)OR 48 , —CO 2 R 49 , —CONR 50 R 51 , —OCONR 53 R 54 , —COR 55 , nitro (—NO 2 ), cyano (—CN), oxo (═O), and a group selected from aryl, heterocycle and —(C 1 -C 6 )alkyl-heterocycle, said group being optionally substituted with one or more (C 1 -C 6 )-alkyl; and

R 36 to R 55 are, independently of one another, H, halo, benzoylbenzyl, or a group selected from (C 1 -C 6 )alkyl, aryl, heteroaryl, heterocycle, —(C 1 -C 6 )alkyl-heterocycle, and —(C 1 -C 6 )alkyl-aryl, said group being optionally substituted with one or more groups selected from halo, CF 3 and (C 1 -C 6 )alkyl; or R 37 -R 38 , R 42 -R 43 , R 50 -R 51 , and/or R 53 -R 54 may together respectively form a heterocycloalkyl.

2. The method according to claim 1 , wherein:

R 1 is H, a (C 1 -C 6 )alkyl or a (C 3 -C 6 )cycloalkyl, or R 1 forms together with R 2 or R 4 a heterocycloalkyl;

R 2 and R 3 are H;

R 2 to R 6 are, independently of one another, H or OR 10 ;

R 10 is H or (C 1 -C 6 )alkyl;

R 7 is H or halo;

R 8 is H; halo; or a group selected from (C 1 -C 6 )alkyl, heterocycle, aryl, heteroaryl, —(C 1 -C 6 )alkyl-aryl, and —(C 1 -C 6 )alkyl-heterocycle, said group being optionally substituted with one or more groups selected from halo, —OR 36 , —NR 37 R 38 , —SR 39 , —S(O)R 40 , —SO 2 R 41 , —SO 2 NR 42 R 43 , —OCOR 44 , —NR 45 COR 46 , —NR 47 C(O)OR 48 , —CO 2 R 49 , —CONR 50 R 51 , —OCONR 53 R 54 , —COR 55 , nitro (—NO 2 ), cyano (—CN), oxo (═O), and a group selected from aryl, heterocycle and —(C 1 -C 6 )alkyl-heterocycle, said group being optionally substituted with one or several-more (C 1 -C 6 )-alkyl;

R 9 is H; halo; or a group selected from (C 1 -C 6 )alkyl, aryl and heteroaryl, said group being optionally substituted with one or more groups selected from halo, —OR 36 , —NR 37 R 38 , —SR 39 , —S(O)R 40 , —SO 2 R 41 , —SO 2 NR 42 R 43 , —OCOR 44 , —NR 45 COR 46 , —NR 47 C(O)OR 48 , —CO 2 R 49 , —CONR 50 R 51 , —OCONR 53 R 54 , —COR 55 , nitro (—NO 2 ), cyano (—CN), oxo (═O), and a group selected from aryl, heterocycle and —(C 1 -C 6 )alkyl-heterocycle, said group being optionally substituted with one or more (C 1 -C 6 )-alkyl;

R 36 to R 55 are, independently of one another, H, halo, benzoylbenzyl, or a group selected from (C 1 -C 6 )alkyl, aryl, heteroaryl, heterocycle, —(C 1 -C 6 )alkyl-heterocycle, and —(C 1 -C 6 )alkyl-aryl, said group being optionally substituted with one or more groups selected from halo, CF 3 or (C 1 -C 6 )alkyl; or R 37 -R 38 , R 42 -R 43 , R 50 -R 51 , and/or R 53 -R 54 may together respectively form a heterocycloalkyl.

3. The method according to claim 1 , wherein R 8 to R 9 are, independently of one another, H; halo; or a group selected from (C 1 -C 6 )alkyl, piperidinyl, morpholinyl, pyrrolidinyl, phenyl, benzyl, thiophenyl, benzimidazolyl or imidazolyl, said group being optionally substituted with one or two groups selected from halo, —OR 36 , —NR 37 R 38 , —SR 39 , —S(O)R 40 , —SO 2 R 41 , —SO 2 NR 42 R 43 , —OCOR 44 , —NR 45 COR 46 , —NR 47 C(O)OR 48 , —CO 2 R 49 , —CONR 50 R 51 , —OCONR 53 R 54 , —COR 55 , nitro (—NO 2 ), cyano (—CN), oxo (═O), —(C 1 -C 6 )alkyl-heterocycle, and an heterocycle group.

4. The method according to claim 1 , wherein R 8 to R 9 are, independently of one another, H, halo, or a phenyl group, said phenyl group being optionally substituted with one or two groups selected from halo, —OR 36 and —(C 1 -C 6 )alkyl-heterocycle.

5. The method according to claim 1 , wherein:

R 7 is H or halo;

R 8 and R 9 are, independently of one another, H, halo, or a phenyl group, said phenyl group being optionally substituted with one or two groups selected from halo or —OR 36 .

6. The method according to claim 1 , wherein R 3 , R 5 and R 6 are H.

7. The method according to claim 1 , wherein R 36 to R 55 are, independently of one another, H, halo, or a group selected from (C 1 -C 6 )alkyl, aryl, heteroaryl, said group being optionally substituted with one or more groups selected from halo, CF 3 or methyl.

8. The method according to claim 1 , wherein the compound is selected from the following compounds:

and the pharmaceutically acceptable salts and solvates thereof.

9. The method according to claim 1 , wherein the compound is selected from the following compounds:

and the pharmaceutically acceptable salts and solvates thereof.

10. The method according to claim 1 , wherein said pharmaceutically acceptable salts of the compound of general formula (I) are hydrobromic acid addition salts.

11. The method according to claim 1 , wherein the patient has a disorder selected from trauma in brain, hepatitis, alcoholic and non-alcoholic steatohepatitis, acute pancreatitis and acute tubular necrosis, heart or kidney transplantation, atherosclerosis, bone marrow failure, viral infection, Crohn's and ulcerative colitis, terminal ileitis, chronic obstructive pulmonary disease or ischemia reperfusion injury.

12. The method according to claim 1 , wherein the patient has a disorder selected from tumour cells extravasation or metastasis.

13. The method according to claim 1 wherein said compound of formula (I) is administered to said patient as a pharmaceutical composition comprising at least one pharmaceutically acceptable excipient.

14. The method according to claim 13 , wherein the patient has a disorder selected from trauma in brain, hepatitis, alcoholic and non-alcoholic steatohepatitis, acute pancreatitis and acute tubular necrosis, heart or kidney transplantation, atherosclerosis, bone marrow failure, viral infection, Crohn's and ulcerative colitis, terminal ileitis, chronic obstructive pulmonary disease or ischemia reperfusion injury.

15. A method for the preservation and/or protection of biological materials comprising placing said biological materials in a medium containing a compound of the following general formula (I)

or a pharmaceutically acceptable salt and/or solvate thereof,

wherein:

R 1 is H, a (C 1 -C 6 )alkyl or a (C 3 -C 6 )cycloalkyl, or R 1 forms together with R 2 or R 4 a heterocycloalkyl;

R 2 to R 6 are, independently of one another, H or OR 10 ;

R 10 is H or (C 1 -C 6 )alkyl;

R 7 to R 9 are, independently of one another, H; halo; or a group selected from (C 1 -C 6 )alkyl, heterocycle, aryl, heteroaryl, —(C 1 -C 6 )alkyl-aryl, and —(C 1 -C 6 )alkyl-heterocycle, said group being optionally substituted with one or more groups selected from halo, —OR 36 , —NR 37 R 38 , —SR 39 , —S(O)R 40 , —SO 2 R 41 , —SO 2 NR 42 R 43 , —OCOR 44 , —NR 45 COR 46 , —NR 47 C(O)OR 48 , —COR 49 , —CONR 50 R 51 , —OCONR 53 R 54 , —COR 55 , nitro (—NO 2 ), cyano (—CN), oxo (═O), and a group selected from aryl, heterocycle and —(C 1 -C 6 )alkyl-heterocycle, said group being optionally substituted with one or more (C 1 -C 6 )-alkyl; and

R 36 to R 55 are, independently of one another, H, halo, benzoylbenzyl, or a group selected from (C 1 -C 6 )alkyl, aryl, heteroaryl, heterocycle, —(C 1 -C 6 )alkyl-heterocycle, and —(C 1 -C 6 )alkyl-aryl, said group being optionally substituted with one or more groups selected from halo, CF 3 or (C 1 -C 6 )alkyl; or R 37 -R 38 , R 42 -R 43 , R 50 -R 51 , and/or R 53 -R 54 may together respectively form a heterocycloalkyl.

16. The method according to claim 2 , wherein R 1 is H, a (C 1 -C 3 )alkyl or R 1 forms together with R 2 or R 4 a heterocycloalkyl.

17. The method according to claim 3 , wherein R 8 to R 9 are, independently of one another, H; halo; or a group selected from (C 1 -C 6 )alkyl, piperidinyl, morpholinyl, pyrrolidinyl, phenyl, benzyl, thiophenyl, benzimidazolyl or imidazolyl, said group being optionally substituted with one or two groups selected from —OR 36 , —NR 37 R 38 , —OCOR 44 , —NR 45 COR 46 , —NR 47 C(O)OR 48 , —CO 2 R 49 , —CONR 50 R 51 , —OCONR 53 R 54 , —COR 55 , —(C 1 -C 6 )alkyl-heterocycle or an heterocycle group.

18. The method according to claim 3 , wherein R 8 to R 9 are, independently of one another, H; halo; or a group selected from (C 1 -C 6 )alkyl, piperidinyl, morpholinyl, pyrrolidinyl, phenyl, benzyl, thiophenyl, benzimidazolyl or imidazolyl, said group being optionally substituted with one or two groups selected from —OR 36 or an —(C 1 -C 6 )alkyl-heterocycle group.

19. The method according to claim 11 , wherein the ischemia reperfusion injury is associated with a myocardial infarction or a stroke.

20. The method according to claim 14 , wherein the ischemia reperfusion injury is associated with a myocardial infarction or a stroke.

21. The method according to claim 15 , wherein the biological materials are cells, tissues, body fluids, organs or microorganisms.